Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation is about someone seeking a doctor in the EU who prescribes spironolactone or bicalutamide for female pattern hair loss, as they are having difficulty finding treatment options beyond Minoxidil in Austria. They are asking for recommendations and are open to direct messages for assistance.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

A 35-year-old with alopecia areata has tried finasteride, topical and oral minoxidil, and dutasteride without success in stopping hair loss. The dermatologist suggests JAK inhibitors, but they are too costly, leading to uncertainty about the cause of hair loss.

The conversation is about an 18-year-old transgender individual seeking advice on discussing hair loss treatments, specifically Minoxidil and finasteride, with a dermatologist. They are preparing for an upcoming appointment to address hair loss concerns.

The user is experiencing scalp irritation and increased hair loss while on vacation, possibly due to hard water and sun exposure. They have stopped using a minoxidil and finasteride spray due to burning sensations and are using a prescribed betamethasone and salicylic acid solution along with ketoconazole shampoo.

Dutasteride at 0.5 mg and 2.5 mg doses may eventually yield similar hair growth results over time, with 0.5 mg being sufficient for many users. Higher doses may not significantly increase benefits and could lead to diminished returns.

The user experienced long-term pain after an FUE hair transplant and is considering Kenacort injections for relief. They also reported brain fog, dizziness, and anxiety after stopping minoxidil and finasteride, and are currently using PRP, microneedling, and rosemary oil for hair maintenance.

Poor gut health may contribute to hair loss and scalp inflammation, with treatments like finasteride, minoxidil, and Nizoral being used. Improving gut health and addressing inflammation might help alleviate symptoms.

Creatine does not increase testosterone or DHT, and there is no evidence it causes hair loss. Some users report improved gym performance and mood with creatine, while others are concerned about potential hair loss, but scientific research does not support these concerns.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

The conversation discusses unconventional methods for hair regrowth, including scalp trauma like burning or microneedling, and compares them to treatments like Minoxidil and Finasteride. It highlights skepticism about these methods and the body's unpredictable healing responses.

The user is experiencing a receding hairline and is considering treatments. They are seeking advice on whether to use finasteride, minoxidil, or both for hair preservation and potential regrowth.

A 25-year-old experiencing hair thinning all over the body and head, despite using minoxidil and having low vitamin D levels, is advised to seek a second opinion from a dermatologist specializing in hair loss. The likely diagnosis is diffuse alopecia areata, which may require treatment with a JAK inhibitor.

Managing seborrheic dermatitis using ketoconazole shampoo, Nizoral, and oils like MCT and coconut oil. The user considers shaving their head and consulting a dermatologist.

A new hair loss treatment reportedly shows a 539% improvement in hair count, but skepticism remains due to unclear placebo results and potential minimal actual hair growth. Many users doubt its effectiveness and market viability, citing high costs and lack of visual proof.

A 28-year-old male experiencing hair thinning is considering minoxidil and finasteride. Minoxidil helps regrow hair, while finasteride prevents further loss; both are usually lifelong treatments.

Matthew McConaughey likely maintains his hair using finasteride, minoxidil, hair transplants, and possibly a hair system. Products like Reginix or rosemary oil are not considered as effective as these treatments.

The user is considering taking 2.5 mg oral minoxidil and 1 mg oral finasteride sublingually to minimize side effects after a hair transplant. They seek advice on the pros and cons of this method, noting a lack of concrete information.

Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.

The user is taking 2.5 mg dutasteride and 5% minoxidil but is not seeing hair regrowth, and is considering adding RU58841. They are experiencing fatigue and low MCV/MCH, possibly related to dutasteride, and are advised to be patient, consider microneedling, and check for iron deficiency.

A 22-year-old male experienced significant hair regrowth after five months using 1mg finasteride and 5mg minoxidil, with plans to switch to dutasteride. He reported emotional changes and thicker eyebrows and eyelashes as side effects.

Prolactin and cortisol are identified as key factors in hair loss, with stress hormones impacting hair shedding. Finasteride and minoxidil are effective treatments, while DHT's role and individual sensitivity are significant factors.

The user experienced severe hair loss despite using Minoxidil and Finasteride and is considering switching to Dutasteride. Others recommend consulting a dermatologist, checking for health issues, and trying Dutasteride and oral Minoxidil.

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

A 42-year-old experienced significant hair regrowth after 12 weeks on an oral combination of finasteride (1 mg) and minoxidil (2.5 mg), with noticeable improvements and no side effects. The user is considering continuing the treatment for a year due to the unexpected positive results.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.